Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
15 participants
INTERVENTIONAL
2015-09-30
2019-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Ischemic Post-conditioning
NCT04068116
Percutaneous Revascularization in Infarction With Late Presentation and Absence of Viability: Effects on Left Ventricular Remodeling and Contractility
NCT05160311
Randomised EValuation of Therapies for microvAscuLar Injury in STEACS
NCT06935383
Post Ten Year Follow up Assessment of a Phase I Trial of Angiogenic Gene Therapy
NCT01174095
Upfront Premedication For Reduction of Microvascular Obstruction and No-reflow in Treating ST-segment Elevation Myocardial Infarction
NCT05393557
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Post Myocardial Infarction
VentriGel will be injected via a MyoStar catheter after NOGA mapping in the 60 day to 3 year window since the first STEMI myocardial infarction
VentriGel
VentriGel will be injected via MyoStar catheter after NOGA mapping
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
VentriGel
VentriGel will be injected via MyoStar catheter after NOGA mapping
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. The subject must be able to provide informed consent
3. At least 60 days and no more than 3 years will have passed since the first ST elevation myocardial infarction (Index STEMI) at time of VentriGel administration
4. The Index STEMI must meet the following criteria:
1. First time diagnosis of STEMI AND;
2. Meet the STEMI criteria of the American College of Cardiology (ACC)/American Heart Association (AHA) (e.g. ST elevation in at least 2 contiguous leads \>0.2 mV in V1, V2 or V3 and/or \>0.1mV in at least two other leads), or new left bundle branch block (LBBB)
5. Evidence of left ventricular remodeling secondary to the myocardial infarction using 2-D echocardiography or cMR;
1. the LVEF must be ≥ 25% and ≤ 45% AND;
2. The left ventricular wall thickness is ≥ 8 mm in target area.
6. Successful percutaneous coronary intervention (PCI) restoring TIMI II of higher flow to infarcted area
7. Negative pregnancy test \[serum human chorionic gonadotropin (βhCG)\] in women of childbearing potential within 24 hours prior to dosing) or if less than 2 years postmenopausal agree to use of adequate contraception during the study.
8. Must be ambulatory, willing and able to comply with protocol, including follow-up visits
9. Subject must be receiving best medical treatment for their post-MI clinical presentation according to the American College of Cardiology (ACC)/American Heart Association (AHA) guidelines
10. For those subjects indicated for heart failure medical therapy, subjects must be on stable therapy including beta-blockers and angiotensin converting enzyme inhibitors, if tolerated, for at least 45 days prior to therapy delivery
Exclusion Criteria
2. NYHA Functional Classification 4 heart failure within the prior 6 months.
3. Significant coronary artery stenosis that may require percutaneous or surgical revascularization within six months of enrollment, as determined by the principal investigator
4. Left ventricular thrombus, left ventricular aneurysm, subjects with post-infarction pericarditis, or subjects with wall motion abnormalities outside the region of the infarct related artery
5. Frequent, recurrent, sustained (\>30 seconds) ventricular tachycardia in 30 days prior to VentriGel administration
6. ECG or 24 hour Holter Monitor with any of the following findings:
* Bifascicular block (left bundle branch block or right bundle branch block plus left hemi-block)
* Higher grade AV block (i.e. 3rd degree)
* Ventricular tachycardia (\>= 5 seconds of VT OR any symptomatic VT)
7. Atrial fibrillation with heart rate greater than 110 bpm.
8. Severe valvular disease (e.g. aortic stenosis of moderate or worse severity, valvular insufficiency requiring surgical repair) or history of heart valve replacement.
9. Known allergy to porcine proteins or prior implantation of a porcine derived medical product including cardiac valves or other ECM products.
10. Etiology of heart failure due to any cause (e.g. hypertrophic cardiomyopathies, restrictive cardiomyopathies, constrictive pericardial disease, amyloidosis, active myocarditis) other than the index MI.
11. Severe peripheral vascular disease that impairs femoral arterial access.
12. Less than 3 years, cancer free, since end of treatment for cancer (with exception of basal cell carcinoma)
13. Alcohol or drug dependency within six months prior to enrollment
14. Cerebrovascular event within the 90 days prior or major surgical procedure or major trauma within the 14 days prior to enrollment
15. Participation, defined as receiving test article, in an experimental clinical study within 30 days prior to administration of VentriGel (i.e. screen failure from other study does not exclude subject)
16. Uncontrolled hypertension defined as systolic blood pressure (SBP) \> 180 mmHg and/or or diastolic blood pressure (DBP) \>110 mmHg
17. Abnormal laboratory values as defined below performed at screening:
* Aspartate aminotransferase \[AST\]/ alanine aminotransferase \[ALT\] ≥ 3 times upper limit of normal (ULN)
* Serum creatinine ≥ 2.0 mg/dL
* Platelet count \< 50,000/mm3
* Hemoglobin \< 9.0 g/dL
* HbA1c \> 9.0%
* PT or aPTT with clinically significant elevations relative to local laboratory norms
18. Any other cardiac or non-cardiac conditions or illness which, in the opinion of the principal investigator, may place subjects at undue risk or compromise the objectives of the study.
19. Institutional interpretation of cMR EF data outside the ≥ 25% and ≤ 45% limits
30 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ventrix, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mercy Gilbert Medical Center
Gilbert, Arizona, United States
Cedars-Sinai Medical Center
Los Angeles, California, United States
University of Florida
Gainesville, Florida, United States
Rush University Medical Center
Chicago, Illinois, United States
Minneapolis Heart Institute
Minneapolis, Minnesota, United States
University of Utah
Salt Lake City, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CV-201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.